Callan JMB Reports Revenue Decline Amid Growth Initiatives

Event summary

  • Callan JMB reported a 13.6% revenue decline to $5.7M in 2025, citing reduced demand for emergency preparedness services.
  • Operating loss widened to $7M from $2.3M in 2024, driven by increased SG&A expenses related to IPO costs.
  • Signed a manufacturing oversight agreement with Attune Biotech for its therapeutic pipeline.
  • Extended Chicago emergency preparedness contract to June 2026 with $1.5M funding increase.
  • Launched Callan JMB Services (India) with a planned temperature-controlled warehouse in Pune.

The big picture

Callan JMB is navigating a challenging period with declining revenues from core emergency preparedness services while investing in growth initiatives in healthcare and food logistics. The company's strategic partnerships and international expansion efforts aim to position it at the center of critical healthcare and national preparedness supply chains, but execution and cost management will be key to long-term success.

What we're watching

Revenue Diversification
Whether healthcare and food logistics initiatives can offset declining emergency preparedness revenues.
Cost Control
The pace at which Callan JMB can reduce SG&A expenses post-IPO to improve profitability.
International Expansion
How the India operations will impact overall growth and operational efficiency.